Integer Holdings Faces Shareholder Investigation Over Alleged Misstatements
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 09 2026
0mins
Should l Buy ITGR?
Source: Globenewswire
- Shareholder Investigation Launched: Grabar Law Office is investigating whether executives of Integer Holdings Corp. breached their fiduciary duties, allowing shareholders to seek corporate reforms and fund recovery, indicating significant governance challenges for the company.
- Allegations of Misstatements: A recently filed federal securities fraud class action alleges that Integer materially misrepresented its competitive position in the EP device market, leading to investor misconceptions about the company's prospects, which could undermine shareholder confidence.
- Sales Decline Risks: Despite claims of strong visibility into customer demand, Integer is reportedly experiencing a sustained deterioration in sales of its EP devices, a fact that was not disclosed, potentially leading to future performance declines and impacting market perception.
- Uncertain Financial Outlook: Molina Healthcare's financial guidance may face substantial cuts due to undisclosed adverse information regarding medical cost trend assumptions, further exacerbating market concerns about its financial health.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ITGR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ITGR
Wall Street analysts forecast ITGR stock price to rise
4 Analyst Rating
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 85.360
Low
75.00
Averages
86.25
High
95.00
Current: 85.360
Low
75.00
Averages
86.25
High
95.00
About ITGR
Integer Holdings Corporation is a medical device contract development and manufacturing company. The Company serves the cardiac rhythm management, neuromodulation, and cardio and vascular markets. Its brands include Greatbatch Medical and Lake Region Medical. The Company’s Cardio & Vascular product line offers a range of components, subassemblies, and finished devices used in interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. Its interventional cardiology portfolio is focused primarily on the design, development and manufacture of catheter and wire-based technologies intended to diagnose and treat cardiac disease. Its electrophysiology products include devices used by electrophysiologists and interventional cardiologists for the treatment of cardiac arrythmias, such as atrial fibrillation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Multiple Companies Face Class Action Lawsuits
- Integer Holdings Lawsuit: Integer Holdings is accused of overstating its competitive position in the EP manufacturing market from July 2024 to October 2025, leading to investor misconceptions about the company's prospects, which could negatively impact its stock price and market trust.
- F5, Inc. Security Incident: F5 failed to disclose a significant security incident during the period from October 2024 to October 2025, placing client security and the company's future prospects at risk, potentially leading to a decline in investor confidence.
- SLM Corporation Delinquency Issues: SLM is alleged to have not disclosed a significant increase in early-stage delinquencies from July to August 2025, misleading investors regarding the effectiveness of its loss mitigation programs, which could affect its financial stability.
- Klarna Group Risk Concealment: Klarna is accused of underestimating the risk of increased loss reserves from September to December 2025, potentially leading to investor misunderstandings about its business prospects, impacting its market performance.
See More
Notice of Class Action Against Integer Holdings
- Class Action Notice: Rosen Law Firm reminds investors who purchased Integer Holdings (NYSE: ITGR) common stock between July 25, 2024, and October 22, 2025, to apply as lead plaintiffs by February 9, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Integer materially overstated its competitive position in the electrophysiology (EP) manufacturing market and failed to disclose a sustained decline in sales of its EP devices, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its strong reputation in the field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure they receive the best representation and support in the class action.
See More
Integer Holdings Faces Class Action Lawsuit Over Misleading Statements
- Lawsuit Background: Rosen Law Firm has alerted investors about a class action lawsuit on behalf of purchasers of Integer Holdings Corporation (NYSE: ITGR) common stock from July 25, 2024, to October 22, 2025, alleging significant exaggeration of its competitive position in the electrophysiology manufacturing market.
- False Statement Allegations: The lawsuit claims that Integer's assertions of strong visibility into customer demand contradicted the reality of deteriorating sales for two of its electrophysiology devices, resulting in investor losses when the truth emerged.
- Market Impact: As the true details became public, investors realized that Integer's positive statements lacked a reasonable basis, potentially leading to significant stock price impacts and revealing serious misguidance regarding the company's growth prospects in the cardiovascular device sector.
- Legal Proceedings Update: Investors wishing to serve as lead plaintiffs in the class action must file their motions with the court by February 9, 2026, indicating their representative role in the litigation, and they do not need to participate in the case to be eligible for recovery.
See More
Integer Holdings Corporation Faces Class Action Lawsuit for Securities Fraud
- Lawsuit Background: Bleichmar Fonti & Auld LLP has filed a class action lawsuit against Integer Holdings Corporation and certain executives for securities fraud, following a significant stock drop due to potential violations of federal securities laws.
- Stock Price Plunge: On October 23, 2025, Integer lowered its 2025 sales guidance to between $1.840 billion and $1.854 billion, below analyst expectations, causing its stock price to plummet from $109.11 to $73.89, a drop of over 32%.
- False Performance Claims: The lawsuit alleges that Integer overstated demand for its electrophysiology devices, while actual sales and demand sharply declined, contradicting the company's public assurances.
- Legal Options: Investors are encouraged to apply to lead the case by February 9, 2026, with BFA offering representation on a contingency fee basis, ensuring no upfront costs for shareholders.
See More
Integer Holdings Faces Securities Class Action Lawsuit
- Lawsuit Deadline: Investors must file lead plaintiff applications by February 9, 2026, for the securities class action against Integer Holdings, involving trades from July 25, 2024, to October 22, 2025, highlighting the urgency of legal proceedings and potential investor rights.
- Sales Guidance Cut: On October 23, 2025, Integer disclosed a lowered full-year 2025 sales guidance of $1.840 billion to $1.854 billion, significantly below analyst expectations, with projected net sales growth of -2% to 2% for 2026, indicating slower market adoption of its products and potential impacts on future performance.
- Stock Price Plunge: Following the sales guidance cut, Integer's stock price plummeted by $35.22, or over 32%, from a closing price of $109.11 on October 22, 2025, to $73.89 on October 23, reflecting market pessimism regarding the company's outlook.
- Legal Liability Allegations: The lawsuit alleges that Integer and certain executives failed to disclose material information during the class period, violating federal securities laws, which could expose the company to significant legal and financial risks, undermining investor confidence.
See More
Reminder for Integer Holdings Shareholder Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Integer Holdings stock between July 25, 2024, and October 22, 2025, to apply as lead plaintiffs by February 9, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Integer materially overstated its competitive position in the electrophysiology market and failed to disclose a sustained decline in sales of two of its devices, resulting in investor losses when the truth emerged.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its success and resources, urging investors to choose counsel with a proven track record.
- Investor Rights Protection: Until the class is certified, investors can select their own counsel or choose to remain absent, ensuring that their ability to share in any potential recovery is not contingent on serving as lead plaintiff, thus protecting their rights.
See More
Multiple Companies Face Class Action Lawsuits
- Integer Holdings Lawsuit: Integer Holdings is accused of overstating its competitive position in the EP manufacturing market from July 2024 to October 2025, leading to investor misconceptions about the company's prospects, which could negatively impact its stock price and market trust.
- F5, Inc. Security Incident: F5 failed to disclose a significant security incident during the period from October 2024 to October 2025, placing client security and the company's future prospects at risk, potentially leading to a decline in investor confidence.
- SLM Corporation Delinquency Issues: SLM is alleged to have not disclosed a significant increase in early-stage delinquencies from July to August 2025, misleading investors regarding the effectiveness of its loss mitigation programs, which could affect its financial stability.
- Klarna Group Risk Concealment: Klarna is accused of underestimating the risk of increased loss reserves from September to December 2025, potentially leading to investor misunderstandings about its business prospects, impacting its market performance.
See More
Notice of Class Action Against Integer Holdings
- Class Action Notice: Rosen Law Firm reminds investors who purchased Integer Holdings (NYSE: ITGR) common stock between July 25, 2024, and October 22, 2025, to apply as lead plaintiffs by February 9, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Integer materially overstated its competitive position in the electrophysiology (EP) manufacturing market and failed to disclose a sustained decline in sales of its EP devices, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its strong reputation in the field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure they receive the best representation and support in the class action.
See More
Integer Holdings Faces Class Action Lawsuit Over Misleading Statements
- Lawsuit Background: Rosen Law Firm has alerted investors about a class action lawsuit on behalf of purchasers of Integer Holdings Corporation (NYSE: ITGR) common stock from July 25, 2024, to October 22, 2025, alleging significant exaggeration of its competitive position in the electrophysiology manufacturing market.
- False Statement Allegations: The lawsuit claims that Integer's assertions of strong visibility into customer demand contradicted the reality of deteriorating sales for two of its electrophysiology devices, resulting in investor losses when the truth emerged.
- Market Impact: As the true details became public, investors realized that Integer's positive statements lacked a reasonable basis, potentially leading to significant stock price impacts and revealing serious misguidance regarding the company's growth prospects in the cardiovascular device sector.
- Legal Proceedings Update: Investors wishing to serve as lead plaintiffs in the class action must file their motions with the court by February 9, 2026, indicating their representative role in the litigation, and they do not need to participate in the case to be eligible for recovery.
See More
Integer Holdings Corporation Faces Class Action Lawsuit for Securities Fraud
- Lawsuit Background: Bleichmar Fonti & Auld LLP has filed a class action lawsuit against Integer Holdings Corporation and certain executives for securities fraud, following a significant stock drop due to potential violations of federal securities laws.
- Stock Price Plunge: On October 23, 2025, Integer lowered its 2025 sales guidance to between $1.840 billion and $1.854 billion, below analyst expectations, causing its stock price to plummet from $109.11 to $73.89, a drop of over 32%.
- False Performance Claims: The lawsuit alleges that Integer overstated demand for its electrophysiology devices, while actual sales and demand sharply declined, contradicting the company's public assurances.
- Legal Options: Investors are encouraged to apply to lead the case by February 9, 2026, with BFA offering representation on a contingency fee basis, ensuring no upfront costs for shareholders.
See More
Integer Holdings Faces Securities Class Action Lawsuit
- Lawsuit Deadline: Investors must file lead plaintiff applications by February 9, 2026, for the securities class action against Integer Holdings, involving trades from July 25, 2024, to October 22, 2025, highlighting the urgency of legal proceedings and potential investor rights.
- Sales Guidance Cut: On October 23, 2025, Integer disclosed a lowered full-year 2025 sales guidance of $1.840 billion to $1.854 billion, significantly below analyst expectations, with projected net sales growth of -2% to 2% for 2026, indicating slower market adoption of its products and potential impacts on future performance.
- Stock Price Plunge: Following the sales guidance cut, Integer's stock price plummeted by $35.22, or over 32%, from a closing price of $109.11 on October 22, 2025, to $73.89 on October 23, reflecting market pessimism regarding the company's outlook.
- Legal Liability Allegations: The lawsuit alleges that Integer and certain executives failed to disclose material information during the class period, violating federal securities laws, which could expose the company to significant legal and financial risks, undermining investor confidence.
See More
Reminder for Integer Holdings Shareholder Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Integer Holdings stock between July 25, 2024, and October 22, 2025, to apply as lead plaintiffs by February 9, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Integer materially overstated its competitive position in the electrophysiology market and failed to disclose a sustained decline in sales of two of its devices, resulting in investor losses when the truth emerged.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its success and resources, urging investors to choose counsel with a proven track record.
- Investor Rights Protection: Until the class is certified, investors can select their own counsel or choose to remain absent, ensuring that their ability to share in any potential recovery is not contingent on serving as lead plaintiff, thus protecting their rights.
See More
